Search Results - "Huang, Zhangzan"

High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study by Su, Yanhong, Zhang, Yarui, Hua, Xin, Huang, Jiajia, Bi, Xiwen, Xia, Wen, Wang, Xinyue, Huang, Zhangzan, Song, Chenge, Zhong, Yongyi, Shi, Yanxia, Wang, Shusen, Fan, Wei, Yuan, Zhongyu

“…Background: Tumor progression following endocrine therapy is considered to indicate resistance to endocrine drugs due to a variety of mechanisms. An…”
Get full text

The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer by Wang, Xinyue, Bi, Xiwen, Huang, Zhangzan, Huang, Jiajia, Xia, Wen, Shi, Wei, Yuan, Zhongyu

“…The significance of androgen receptor (AR) in metastatic breast cancer (MBC) remains unclear, and it is still largely unknown how AR expression level…”
Get full text

Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer by Wang, Xinyue, Li, JiBin, Shi, Wei, Huang, Zhangzan, Xia, Wen, Huang, Jiajia, Su, Yanhong, Wang, Shusen, Shi, Yanxia, Bi, Xiwen, Yuan, Zhongyu

“…Lessons Learned Moxifloxacin plus continuation of the previous treatment of physician's choice shows promising efficacy in patients with metastatic breast…”
Get full text

Abstract 3282: Endocrine resistance genes driving cross-resistance to current combination therapies in HR-positive breast cancer by Huang, Zhangzan, Wortelboer, Noor, Beaufort, Corine, Ortak, Seda N., Chan, Da-wei, Dag, Hamit H., Helmijr, Jean, Martens, John, Jansen, Maurice

“…Introduction: Treatment failure to multiple treatment lines in hormone receptor positive (HR+) patients brings cross-resistance into the stage. The study aimed…”
Get full text

The prognostic value of AR in HER2-enriched metastatic breast cancer by Wang, Xinyue, Bi, Xiwen, Huang, Zhangzan, Huang, Jiajia, Xia, Wen, Shi, Wei, Yuan, Zhongyu

“…The significance of androgen receptor (AR) in metastatic breast cancer (MBC) remains unclear, and it is still largely unknown how AR expression level…”
Get full text

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus by Duan, Fangfang, Song, Chenge, Ma, Yuyu, Jiang, Kuikui, Xu, Fei, Bi, Xiwen, Huang, Jiajia, Hong, Ruoxi, Huang, Zhangzan, Lu, Qianyi, Yuan, Zhongyu, Wang, Shusen, Xia, Wen

“…There are no clinically available prognostic models for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative…”
Get full text